In order to test whether the therapeutic benefit of the Ad-IL-12/GPC3 vaccine regimen in the tumor model depended on CD8+ T lymphocytes, we used anti-CD8 monoclonal antibodies (mAbs) to carry out a deletion test. This evidence concerns the gene GPC3 and neoplasm.